NCT06081998

Brief Summary

In This experiment, the investigators would like to test following hypotheses regarding the influence of sleep deprivation on itch:

  • To investigate similarity and differences between itch and pain by comparing the effect of sleep deprivation in them.
  • To evaluate the inflammatory state induced by sleep fragmentation via the analysis of C-reactive protein (CRP) levels from blood samples.
  • To correlate the anxiety and depression scores (evaluated through questionnaires) with itch and pain sensitivity and evaluate how they are affected by sleep. In This experiment, the investigators would like to test following hypotheses regarding the influence of sleep fragmentation on itch:
  • To investigate similarity and differences between itch and pain by comparing the effect of sleep deprivation in them.
  • To evaluate the inflammatory state induced by sleep fragmentation via the analysis of C-reactive protein (CRP) levels from blood samples.
  • To correlate the anxiety and depression scores (evaluated through questionnaires) with itch and pain sensitivity and evaluate how they are affected by sleep deprivation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
8mo left

Started Nov 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Nov 2023Dec 2026

First Submitted

Initial submission to the registry

October 2, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

October 13, 2023

Completed
19 days until next milestone

Study Start

First participant enrolled

November 1, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

December 20, 2023

Status Verified

December 1, 2023

Enrollment Period

1.2 years

First QC Date

October 2, 2023

Last Update Submit

December 14, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • Assessment of itch

    Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'

    Day 1: 1 minute after every itch inductions

  • Assessment of itch

    Immediately following the itch provocations, participants will be instructed to rate the itch intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no itch' and 100 'worst itch imaginable'

    Day 2: 1 minute after every itch inductions

  • Assessment of pain

    Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'.

    Day 1: 1 minute after every itch inductions

  • Assessment of pain

    Immediately following the itch provocations, participants will be instructed to rate the pain intensity for 10 minutes using a digital visual analogue scale (VAS; eVAS Software: Aalborg, University, Denmark), on a tablet. The scale will be measured from 0 to 100, where 0 represents 'no pain' and 100 'worst pain imaginable'.

    Day 2: 1 minute after every itch inductions

Secondary Outcomes (36)

  • Microvascular reactivity

    Day 1: 10 minutes after every itch inductions

  • Microvascular reactivity

    Day 2: 10 minutes after every itch inductions

  • Touch Pleasantness (TP)

    Day 1: 10 minutes after every itch inductions

  • Touch Pleasantness (TP)

    Day 2: 10 minutes after every itch inductions

  • Mechanically evoked itch (MEI), intensity approach

    Day 1: 10 minutes after every itch inductions

  • +31 more secondary outcomes

Study Arms (1)

Sleep deprivation

EXPERIMENTAL

This subproject will be conducted in two sessions separated by three nights of sleep deprivation. Each session will last approximately 2 hours. At the beginning of the first visit and after the last visit, 9 ml of blood will be drawn, and plasma will be isolated. After plasma isolation, the CRP concentration will be analyzed. In each forearm of the participant, a 4x4 cm area will be selected as Area of Interest (AOI). In these selected areas, itch will be induced in both sessions using histamine and cowhage and several tests will be conducted.

Other: HistamineOther: Cowhage

Interventions

Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds

Sleep deprivation
CowhageOTHER

25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration

Sleep deprivation

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men and women
  • years
  • Speak and understand English
  • Access to a smartphone during the experimental nights

You may not qualify if:

  • Pregnancy or lactation
  • Drug addiction defined as any use of cannabis, opioids, or other drugs
  • Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses (psychiatric diagnosis) that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia etc.)
  • Moles, wounds, scars, or tattoos in the area to be treated or tested
  • Current use of medications that may affect the trial such as antihistamines and pain killers.
  • Skin diseases
  • Consumption of alcohol or painkillers 24 hours before the study days and between these
  • Acute or chronic pain and itch
  • Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)
  • Lack of ability to cooperate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aalborg University

Aalborg, 9620, Denmark

RECRUITING

MeSH Terms

Conditions

Sleep Deprivation

Interventions

Histamine

Condition Hierarchy (Ancestors)

DyssomniasSleep Wake DisordersNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMental Disorders

Intervention Hierarchy (Ancestors)

Biogenic MonoaminesBiogenic AminesAminesOrganic ChemicalsEthylaminesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsAutacoidsInflammation MediatorsBiological Factors

Central Study Contacts

kristian KS Petersen

CONTACT

Silvia Lo Vecchio

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
Participant will be blinded about application of pruritogens.
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Model Details: The participants will be instructed to stay awake for 24 hours following the baseline session of this subproject.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

October 2, 2023

First Posted

October 13, 2023

Study Start

November 1, 2023

Primary Completion

December 30, 2024

Study Completion (Estimated)

December 31, 2026

Last Updated

December 20, 2023

Record last verified: 2023-12

Locations